Predictors of in-hospital mortality for bloodstream infections caused by Enterobacter species or Citrobacter freundii

Pharmacotherapy

Volumn 27, Issue 2, 2007, Pages 191-199

  Deal, Eli N ^a   Micek, Scott T ^a   Ritchie, David J ^a,b   Reichley, Richard M ^c   Dunne Jr , W Michael ^d   Kollef, Marin H ^d  

^a BARNES JEWISH HOSPITAL   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

^c Center for Healthcare Quality and Effectiveness   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AmpC lactamases; Bacteremia; Citrobacter freundii; Enterobacter aerogenes; Enterobacter cloacae

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; COTRIMOXAZOLE; GENTAMICIN; HYPERTENSIVE FACTOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM ISOLATE; CITROBACTER FREUNDII; ENTEROBACTER; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; FEMALE; HUMAN; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; RISK FACTOR; UNIVARIATE ANALYSIS;

AGED; BACTEREMIA; CEPHALOSPORINS; CITROBACTER FREUNDII; COHORT STUDIES; DRUG RESISTANCE; ENTEROBACTER; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RESPIRATION, ARTIFICIAL; RETROSPECTIVE STUDIES; STATISTICS AS TOPIC; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 33846798402     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.2.191     Document Type: Article

References (37)

1. Blot S, Vandewoude K, De Bacquer D, Colardyn F. Nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clin Infect Dis 2002;34:1600-6.
2. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 2005;41:848-54.
3. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2003, issued August 2003. Am J Infect Control 2003;31:481-98.
4. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85.
5. Pfaller MA, Jones RN, Marshall SA, et al. Inducible AmpC β-lactamase-producing gram-negative bacilli from bloodstream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis 1997;28:211-19.
6. Raymond DP, Pelletier SJ, Crabtree TD, Evans HL, Pruett TL, Sawyer RG. Impact of antibiotic-resistant gram-negative bacilli infections on outcome in hospitalized patients. Crit Care Med 2003;31:1035-41.
7. Blot SI, Vandewoude KH, Colardyn FA. Evaluation of outcome in critically ill patients with nosocomial Enterobacter bacteremia: results of a matched cohort study. Chest 2003;123:1208-13.
8. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002;162:185-90.
9. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome. Clin Infect Dis 2004;39:812-18.
10. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001;32(suppl 2):S94-103.
11. Barlow M, Hall BG. Origin and evolution of the AmpC β-lactamases of Citrobacter freundii. Antimicrob Agents Chemother 2002;46:1190-8.
12. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585-90.
13. Conceicao T, Faria N, Lito L, Melo Cristino J, Salgado MJ, Duarte A. Diversity of chromosomal AmpC β-lactamases from Enterobacter cloacae isolates in a Portuguese hospital. FEMS Microbiol Lett 2004;230:197-202.
14. Conus P, Francioli P. Relationship between ceftriaxone use and resistance of Enterobacter species. J Clin Pharm Ther 1992;17:303-5.
15. Jacobson KL, Cohen SH, Inciardi JF, et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I β-lactamase-producing organisms. Clin Infect Dis 1995;21:1107-13.
16. Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 2001;45:2628-30.
17. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005;49:1306-11.
18. Muller A, Lopez-Lozano JM, Bertrand X, Talon D. Relationship between ceftriaxone use and resistance to third-generation cephalosporins among clinical strains of Enterobacter cloacae. J Antimicrob Chemother 2004;54:173-7.
19. Dunne WM Jr, Hardin DJ. Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp., Citrobacter spp., and Serratia spp. J Clin Microbiol 2005;43:5945-9.
20. Bailey TC, Ritchie DJ, McMullin ST, et al. A randomized, prospective evaluation of an interventional program to discontinue intravenous antibiotics at two tertiary care teaching institutions. Pharmacotherapy 1997;17:277-81.
21. Woodward RS, Medoff G, Smith MD, Gray JL III. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital. Am J Med 1987;83:817-23.
22. Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. Chest 2004;125:1791-9.
23. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985;13:818-29.
24. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med 1993;118:201-10.
25. Kim BN, Lee SO, Choi SH, et al. Outcome of antibiotic therapy for third-generation cephalosporin-resistant gram-negative bacteraemia: an analysis of 249 cases caused by Citrobacter, Enterobacter and Serratia species. Int J Antimicrob Agents 2003;22:106-11.
26. Kim PW, Harris AD, Roghmann MC, Morris JG Jr, Strinivasan A, Perencevich EN. Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible Citrobacter freundii in hospitalized patients. Antimicrob Agents Chemother 2003;47:2882-7.
27. Lee SO, Kim YS, Kim BN, Kim MN, Woo JH, Ryu J. Impact of previous use of antibiotics on development of resistance to extended-spectrum cephalosporins in patients with Enterobacter bacteremia. Eur J Clin Microbiol Infect Dis 2002;21:577-81.
28. Schwaber MJ, Graham CS, Sands BE, Gold HS, Carmeli Y. Treatment with a broad-spectrum cephalosporin versus piperacillin-tazobactam and the risk for isolation of broad-spectrum cephalosporin-resistant Enterobacter species. Antimicrob Agents Chemother 2003;47:1882-6.
29. Chen YS, Wong WW, Fung CP, Yu KW, Liu CY. Clinical features and antimicrobial susceptibility trends in Citrobacter freundii bacteremia. J Microbiol Immunol Infect 2002;35:109-14.
30. Kim BN, Woo JH, Ryu J, Kim YS. Resistance to extended-spectrum cephalosporins and mortality in patients with Citrobacter freundii bacteremia. Infection 2003;31:202-7.
31. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 2003;31:2742-51.
32. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000;118:146-55.
33. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999;115:462-74.
34. Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31(suppl 4):S131-8.
35. Johnson CC, Livornese L, Gold MJ, Pitsakis PG, Taylor S, Levison ME. Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula. J Antimicrob Chemother 1995;35:765-73.
36. Jones RN, Pfaller MA, Doern GV, Erwin ME, Hollis RJ, for the Cefepime Study Group. Antimicrobial activity and spectrum investigation of eight broad-spectrum β-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Diagn Microbiol Infect Dis 1998;30:215-28.
37. Sanders WE Jr, Tenney JH, Kessler RE. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 1996;23:454-61.